AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24754066 — intervention group
Group type: COMPARATOR
Intervention: Antisecretory therapy
Number of subjects: 112
Study 24754066 — intervention group
Group type: COMPARATOR
Intervention: Treatment for CHD only
Number of subjects: 112
Study 22422931 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified Group (SG) - separation of the sympathetic chain at T2 and T3
Number of subjects: 45
Study 22422931 — intervention group
Group type: COMPARATOR
Intervention: Conventional Group (CG) - excision of T2 and T3 ganglia
Number of subjects: 45
Study 21250572 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerabien ZR (CZR)
Number of subjects: 90
Study 21250572 — intervention group
Group type: EXPERIMENTAL
Intervention: GC Initial (GCI)
Number of subjects: 90
Study 21250572 — intervention group
Group type: EXPERIMENTAL
Intervention: Lava Ceram (LC)
Number of subjects: 90
Study 21250572 — intervention group
Group type: COMPARATOR
Intervention: Control (VO)
Number of subjects: 90
Study 18999087 — intervention group
Group type: EXPERIMENTAL
Intervention: Health maintenance reminders via PHR
Number of subjects: 0
Study 18999087 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 16442886 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analyses in RCTs
Number of subjects: 63
Study 16442886 — intervention group
Group type: EXPERIMENTAL
Intervention: Large RCTs (> 500 patients)
Number of subjects: 63
Study 16442886 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall results (positive/negative) and CONSORT adoption
Number of subjects: 63
Study 12765426 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 400 microg q.i.d. for 28 days
Number of subjects: 15
Study 12765426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 11116699 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% dorzolamide
Number of subjects: 27
Study 11116699 — intervention group
Group type: COMPARATOR
Intervention: 0.5% apraclonidine
Number of subjects: 27
Study 10169531 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton 600 mg QID
Number of subjects: 278
Study 10169531 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton 600 or 800 mg TID
Number of subjects: 278
Study 10169531 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton 600 or 800 mg BID
Number of subjects: 278
Study 8316882 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgery
Number of subjects: 50
Study 8316882 — intervention group
Group type: COMPARATOR
Intervention: Standard surgery
Number of subjects: 50
Study 3323263 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 75
Study 3323263 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 75
Study 3323263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 29164421 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib (600 mg/day; 3 weeks-on/1 week-off) plus letrozole (2.5 mg/day; continuous)
Number of subjects: 668
Study 29164421 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus letrozole (2.5 mg/day; continuous)
Number of subjects: 668
Study 26408375 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (COCs)
Number of subjects: 20
Study 26408375 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (COCs) with doxycycline 40 mg
Number of subjects: 20
Study 26408375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 24556098 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon (PCB) angioplasty
Number of subjects: 220
Study 24556098 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent
Number of subjects: 220
Study 22170412 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg twice daily)
Number of subjects: 29
Study 22170412 — intervention group
Group type: COMPARATOR
Intervention: Meloxicam (10 mg once daily)
Number of subjects: 29
Study 22170412 — intervention group
Group type: COMPARATOR
Intervention: Meloxicam
Number of subjects: 29
Study 22170412 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 29
Study 20159131 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer
Number of subjects: 60
Study 20159131 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensor
Number of subjects: 60
Study 18627323 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive containing 20 microg ethinylestradiol/75 microg gestodene (Group A)
Number of subjects: 70
Study 18627323 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive containing 30 microg ethinylestradiol/75 microg gestodene (Group B)
Number of subjects: 70
Study 16080277 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil 900 mg tablet (test formulation)
Number of subjects: 36
Study 16080277 — intervention group
Group type: COMPARATOR
Intervention: Gemfibrozil 900 mg tablet (reference formulation)
Number of subjects: 36
Study 11821720 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg)
Number of subjects: 42
Study 11821720 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine GITS (30-60 mg)
Number of subjects: 42
Study 10355007 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine varnish mouthguard (3.0% chlorhexidine varnish)
Number of subjects: 46
Study 10355007 — intervention group
Group type: COMPARATOR
Intervention: Placebo varnish mouthguard
Number of subjects: 46
Study 8543496 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 3125
Study 8543496 — intervention group
Group type: COMPARATOR
Intervention: Comparator agents (cephalosporins, imipenem/cilastatin)
Number of subjects: 3125
Study 1771090 — intervention group
Group type: COMPARATOR
Intervention: 75 mg amitriptyline
Number of subjects: 34
Study 1771090 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg amitriptyline + 3 mg flupentixol
Number of subjects: 34
Study 7130553 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (5 mg/kg)
Number of subjects: 5
Study 7130553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 31070507 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency Access Button (EAB) allowing callers to bypass the telephone queue
Number of subjects: 217510
Study 31070507 — intervention group
Group type: EXPERIMENTAL
Intervention: EAB users
Number of subjects: 217510
Study 31070507 — intervention group
Group type: COMPARATOR
Intervention: EAB non-users (3.3% with EAB option and 1.7% without EAB option)
Number of subjects: 217510
Study 31070507 — intervention group
Group type: EXPERIMENTAL
Intervention: EAB use rated by triage professionals
Number of subjects: 217510
Study 28688622 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20mg daily for 10 days (n=21)
Number of subjects: 65
Study 28688622 — intervention group
Group type: COMPARATOR
Intervention: Placebo 20mg daily for 10 days (n=23)
Number of subjects: 65
Study 26390517 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 100
Study 26390517 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 100
Study 24739815 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 40
Study 24739815 — intervention group
Group type: COMPARATOR
Intervention: Sham Electroacupuncture (SEA)
Number of subjects: 40
Study 22823858 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 87
Study 22823858 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 87
Study 22823858 — intervention group
Group type: COMPARATOR
Intervention: Both CBT and ACT
Number of subjects: 87
Study 20435692 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (BMI > 32 kg/m(2))
Number of subjects: 171
Study 20435692 — intervention group
Group type: COMPARATOR
Intervention: Placebo (BMI > 32 kg/m(2))
Number of subjects: 171
Study 20435692 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (BMI < or = 32 kg/m(2))
Number of subjects: 171
Study 20435692 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) (BMI < or = 32 kg/m(2))
Number of subjects: 171
Study 20435692 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Metformin plus CC (BMI < or = 32 kg/m(2))
Number of subjects: 171
Study 18043425 — intervention group
Group type: EXPERIMENTAL
Intervention: Plano spectacles with 1 Delta BU, 2 Delta BO, 2 Delta BI prism power
Number of subjects: 9
Study 18043425 — intervention group
Group type: COMPARATOR
Intervention: Control (plano spectacles)
Number of subjects: 9
Study 18043425 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 Delta vertical prism
Number of subjects: 9
Study 18043425 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 Delta base out and 1.0 Delta base in
Number of subjects: 9
Study 18043425 — intervention group
Group type: EXPERIMENTAL
Intervention: Readymade spectacles
Number of subjects: 9
Study 16237140 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol B (CT at 90 kV with 100 mL contrast material)
Number of subjects: 40
Study 16237140 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol C (CT at 90 kV with 80 mL contrast material)
Number of subjects: 40
Study 16237140 — intervention group
Group type: COMPARATOR
Intervention: Protocol A (CT at 120 kV with 100 mL of contrast material)
Number of subjects: 40
Study 16237140 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 kV (protocols B and C)
Number of subjects: 40
Study 12394963 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitrogen oxide
Number of subjects: 0
Study 12394963 — intervention group
Group type: COMPARATOR
Intervention: Oxygen
Number of subjects: 0
Study 10855800 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated, timed, recurring Master's level social work intervention
Number of subjects: 0
Study 10855800 — intervention group
Group type: COMPARATOR
Intervention: Standard, mandated social work services
Number of subjects: 0
Study 7483486 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbott ELISA
Number of subjects: 403
Study 7483486 — intervention group
Group type: EXPERIMENTAL
Intervention: Murex ELISA
Number of subjects: 403
Study 7483486 — intervention group
Group type: EXPERIMENTAL
Intervention: Ortho ELISA
Number of subjects: 403
Study 7483486 — intervention group
Group type: EXPERIMENTAL
Intervention: RIBA-2
Number of subjects: 403
Study 7483486 — intervention group
Group type: COMPARATOR
Intervention: Probit analysis
Number of subjects: 403
Study 2262581 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine rinse
Number of subjects: 15
Study 2262581 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline rinse
Number of subjects: 15
Study 2262581 — intervention group
Group type: COMPARATOR
Intervention: Commercially available toothpaste and gel products
Number of subjects: 15
Study 2262581 — intervention group
Group type: EXPERIMENTAL
Intervention: Stannous fluoride products
Number of subjects: 15
Study 2262581 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan products
Number of subjects: 15
Study 6680722 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-min tape of a woman's voice at 80 db SPL
Number of subjects: 30
Study 6680722 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-min tape of random noise
Number of subjects: 30
Study 6680722 — intervention group
Group type: COMPARATOR
Intervention: Control (no stimulus presentation)
Number of subjects: 30
Study 6680722 — intervention group
Group type: EXPERIMENTAL
Intervention: Random noise
Number of subjects: 30
Study 31324862 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.05 mg/kg
Number of subjects: 65
Study 31324862 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg/kg
Number of subjects: 65
Study 31324862 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine 0.25 mg/kg
Number of subjects: 65
Study 28043163 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Adherence Report (NAR-M)
Number of subjects: 84
Study 28043163 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Adherence Report Scale (MARS)
Number of subjects: 84
Study 28043163 — intervention group
Group type: COMPARATOR
Intervention: Electronic adherence monitoring
Number of subjects: 84
Study 27409278 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief training on existing internet-based hearing healthcare (IHHC) websites
Number of subjects: 27
Study 27409278 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 27
Study 24959775 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 200mg
Number of subjects: 171
Study 24959775 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 400mg
Number of subjects: 171
Study 24959775 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 800mg
Number of subjects: 171
Study 24959775 — intervention group
Group type: COMPARATOR
Intervention: Control group (no drugs)
Number of subjects: 171
Study 22198441 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram plus omega-3 fatty acids (900 mg eicosapentaenoic acid, 200 mg docosahexaenoic acid, 100 mg other omega-3 fatty acids, two 1 g capsules twice daily)
Number of subjects: 42
Study 22198441 — intervention group
Group type: COMPARATOR
Intervention: Citalopram plus placebo (olive oil, two 1 g capsules per day)
Number of subjects: 42
Study 19750404 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee consumption
Number of subjects: 10
Study 19750404 — intervention group
Group type: COMPARATOR
Intervention: Water consumption
Number of subjects: 10
Study 20528992 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquacel Ag dressing, changed every 3 days
Number of subjects: 70
Study 20528992 — intervention group
Group type: COMPARATOR
Intervention: 1% silver sulfadiazine, changed daily
Number of subjects: 70
Study 16286208 — intervention group
Group type: EXPERIMENTAL
Intervention: Headgear (HG)
Number of subjects: 65
Study 16286208 — intervention group
Group type: EXPERIMENTAL
Intervention: Fränkel function regulator (FR)
Number of subjects: 65
Study 12369079 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment for capsaicin-induced coughing
Number of subjects: 0
Study 12369079 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin at escalating levels
Number of subjects: 0
Study 12369079 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-linear autoregressive model for count data
Number of subjects: 0
Study 9713448 — intervention group
Group type: COMPARATOR
Intervention: L‐NAME 54 mg
Number of subjects: 28
Study 9713448 — intervention group
Group type: COMPARATOR
Intervention: L‐NAME 170 mg
Number of subjects: 28
Study 9713448 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 28
Study 7868876 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1.5 ml/min saline) during exercise test
Number of subjects: 18
Study 7868876 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (9.5 micrograms/kg per min) during exercise test
Number of subjects: 18
Study 7868876 — intervention group
Group type: COMPARATOR
Intervention: Rest (no intervention)
Number of subjects: 18
Study 2974874 — intervention group
Group type: EXPERIMENTAL
Intervention: High speed and density condition (75% correct threshold of 0.66 degrees)
Number of subjects: 0
Study 2974874 — intervention group
Group type: EXPERIMENTAL
Intervention: General condition (75% correct threshold of 1.2 degrees)
Number of subjects: 0
Study 2974874 — intervention group
Group type: EXPERIMENTAL
Intervention: Displays of 63-10 dots
Number of subjects: 0
Study 2974874 — intervention group
Group type: EXPERIMENTAL
Intervention: Displays of only 2 dots
Number of subjects: 0
Study 2974874 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed effect
Number of subjects: 0
Study 2974874 — intervention group
Group type: EXPERIMENTAL
Intervention: Angle of approach to the surface
Number of subjects: 0
Study 31907625 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan toothpaste
Number of subjects: 30
Study 31907625 — intervention group
Group type: COMPARATOR
Intervention: Placebo toothpaste
Number of subjects: 30
Study 30575490 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified FOLFIRINOX regimen (oxaliplatin 85 mg/m², irinotecan 180 mg/m², leucovorin 400 mg/m², fluorouracil 2400 mg/m² every 2 weeks for 24 weeks)
Number of subjects: 493
Study 30575490 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (1000 mg/m² on days 1, 8, and 15 every 4 weeks for 24 weeks)
Number of subjects: 493
Study 27056608 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (0.5 mg/kg of body weight), administered over 40 minutes, twice weekly for up to 4 weeks
Number of subjects: 68
Study 27056608 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (0.5 mg/kg of body weight), administered over 40 minutes, thrice weekly for up to 4 weeks
Number of subjects: 68
Study 27056608 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo, administered over 40 minutes, twice weekly for up to 4 weeks
Number of subjects: 68
Study 27056608 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo, administered over 40 minutes, thrice weekly for up to 4 weeks
Number of subjects: 68
Study 27056608 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label ketamine (0.5 mg/kg of body weight), twice weekly
Number of subjects: 68
Study 27056608 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label ketamine (0.5 mg/kg of body weight), thrice weekly
Number of subjects: 68
Study 24039238 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional pulmonary rehabilitation (CPR)
Number of subjects: 0
Study 24039238 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency chest wall oscillation (HFCWO)
Number of subjects: 0
Study 23157084 — intervention group
Group type: EXPERIMENTAL
Intervention: Supreme Laryngeal Mask Airway (SLMA)
Number of subjects: 100
Study 23157084 — intervention group
Group type: COMPARATOR
Intervention: Proseal Laryngeal Mask Airway (PLMA)
Number of subjects: 100
Study 20483152 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose chemotherapy
Number of subjects: 35
Study 18762639 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment for upper lumbar herniations (L2-L3 or L3-L4)
Number of subjects: 1190
Study 18762639 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment for L5-S1 herniations
Number of subjects: 1190
Study 18762639 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment for L4-L5 herniations
Number of subjects: 1190
Study 15939209 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in blood lead levels from 26.3 (SD=12.0) to 8.3 (SD=6.9) microg/dL over 4 years
Number of subjects: 27
Study 15939209 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurobehavioral Evaluation System 2 (C‐NES II) assessments
Number of subjects: 27
Study 15939209 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized questionnaire for chronic symptoms
Number of subjects: 27
Study 12632413 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 0
Study 12632413 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 0
Study 12632413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12632413 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Only index
Number of subjects: 0
Study 12632413 — intervention group
Group type: EXPERIMENTAL
Intervention: All Core Data Set index
Number of subjects: 0
Study 12632413 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessor Only index
Number of subjects: 0
Study 12632413 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessor + ESR index
Number of subjects: 0
Study 12632413 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient + ESR index
Number of subjects: 0
Study 10535720 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidapril (5 mg daily for 3 to 6 months)
Number of subjects: 126
Study 10535720 — intervention group
Group type: COMPARATOR
Intervention: Control group (no imidapril)
Number of subjects: 126
Study 8767243 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP maintained between 55 and 65 mmHg (Group 1)
Number of subjects: 27
Study 8767243 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP maintained above 70 mmHg using norepinephrine infusion (Group 2)
Number of subjects: 27
Study 1866527 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 15
Study 1866527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 6625217 — intervention group
Group type: EXPERIMENTAL
Intervention: isoflurane (I)
Number of subjects: 148
Study 6625217 — intervention group
Group type: COMPARATOR
Intervention: halothane (H)
Number of subjects: 148
Study 31657166 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 104
Study 31657166 — intervention group
Group type: COMPARATOR
Intervention: Sham Electroacupuncture (sham EA)
Number of subjects: 104
Study 31657166 — intervention group
Group type: COMPARATOR
Intervention: Epidural Block (EB)
Number of subjects: 104
Study 30356854 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment by radiologist, chiropractor, and second-year resident of rheumatology
Number of subjects: 50
Study 30356854 — intervention group
Group type: EXPERIMENTAL
Intervention: Present classifications for cervical degenerative findings
Number of subjects: 50
Study 26848137 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-300 mg volanesorsen
Number of subjects: 80
Study 26848137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 24293339 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care (n = 315)
Number of subjects: 630
Study 24293339 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 315)
Number of subjects: 630
Study 23072556 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye muscle surgery
Number of subjects: 144
Study 23072556 — intervention group
Group type: COMPARATOR
Intervention: Active monitoring
Number of subjects: 144
Study 19727551 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh hernioplasty (Group II)
Number of subjects: 80
Study 19727551 — intervention group
Group type: COMPARATOR
Intervention: Conventional fascial repair (Group I)
Number of subjects: 80
Study 16947035 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient evaluation of information
Number of subjects: 90
Study 16947035 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient evaluation of their physician's decision policy
Number of subjects: 90